Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.

Trial Details

NCT ID
NCT05218889
Phase
PHASE1 / PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • surufatinib + camrelizumab + nab-paclitaxel + S-1
  • nab-paclitaxel + gemcitabine
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Have fully understood this study and voluntarily signed the informed consent form;
  • Patients with histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma;
  • Age 18-75 years old (inclusive);
  • No prior systemic therapy for advanced pancreatic carcinoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →